Immuno AG was a major[1] pharmaceutical company founded in 1960 by Dr. Otto Schwarz & Dr. Hans Eibl[2] with headquarters in Vienna, Austria.[3]
In 1996 the company was acquired by Baxter for $715 million.[4]
^Whiteside, R. M.; Wilson, A.; Blackburn, S.; Hörnig, S. E.; Wilson, C. P. (6 December 2012). Major Companies of Europe 1990/91 Volume 3: Major Companies of Western Europe Outside the European Economic Community. Springer Science & Business Media. ISBN 9789400908017 – via Google Books.
^Stern, Joe. "In Memoriam of Dr. Otto Schwarz - Plasma Protein Therapeutics Association (PPTA)".
^"Immuno AG".
^Thomas M. Burton (30 August 1996). "Baxter Confirms Pact To Acquire Immuno". Wall Street Journal.
ImmunoAG was a major pharmaceutical company founded in 1960 by Dr. Otto Schwarz & Dr. Hans Eibl with headquarters in Vienna, Austria. In 1996 the company...
Baxalta. In 2016 Baxalta was acquired by Shire plc for $32bn. ImmunoAG: Baxter purchased ImmunoAG in 1996 in an effort to keep up with competitors, for $715m...
Crescent Society sued the Health Ministry and Institut Mérieux of France and ImmunoAG of Austria, two corporations who either acquired or succeeded the companies...
ImmunoGen, Inc. was a biotechnology company focused on the development of antibody-drug conjugate (ADC) therapeutics for the treatment of cancer. ImmunoGen...
would never seek to impose the death penalty. In an important libel case, ImmunoAG v. J. Moor-Jankowski (1991), Kaye ruled for the defendant, the editor...
of ligand binding assays instead of strictly "immuno" assays, though the name carried the original "immuno" because of the common use and history of development...
potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently...
her doctoral studies, followed by post-doctoral work, in industry, at ImmunoAG. Her doctorate was awarded by the University of Natural Resources and...
in personal or public collections: Austrian state gallery Belvedere; ImmunoAG; Municipal Gallery in Traun; Kunstlerhaus München; Art Visionary Collection...
Primatology criticizing the Austrian manufacturer ImmunoAG, for its treatment of animals in its research. Immuno responded by charging McGreal with libel. Although...
partnership with Celgene, developing metabolic immuno-oncology therapies and licensing AG-221 as well as AG-881 to Celgene, potentially garnering Agios $120...
1007/s12325-017-0612-x. PMC 5656728. PMID 28983798. Hoos A (April 2016). "Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations". Nature Reviews...
C.H. Boehringer Sohn AG & Co. KG is the parent company of the Boehringer Ingelheim group, which was founded in 1885 by Albert Boehringer (1861–1939) in...
Pharmaceuticals, developing metabolic immuno-oncology therapies. In October 2016, the company acquired EngMab AG for $600 million. In January 2017, the...
the antigen (with a test such as ELISA or antigen microarray assay) or immuno-dot blot. The most productive and stable clone is then selected for future...
tol-DCs, tDCs, or DCregs) are heterogenous pool of dendritic cells with immuno-suppressive properties, priming immune system into tolerogenic state against...
instability. A study found THCA and unheated Cannabis sativa extracts exert immuno-modulating effect, not mediated by the cannabinoid CB1 and CB2 receptor...
(20): 2090–2098. doi:10.1056/NEJMoa0808455. PMID 19439743. Williams DJ, Habib AG, Warrell DA (August 2018). "Clinical studies of the effectiveness and safety...
with Regeneron Pharmaceuticals to discover, develop, and commercialize new immuno-oncology drugs, which could generate more than $2 billion for Regeneron...
Immunocore announced a Phase 3 data readout for tebentafusp in the field of immuno-oncology. In Jan 2022 the US FDA approved tebentafusp-tebn for HLA-A*02:01-positive...
of Eligard, EndoTAG, and RhuDex. The company then shifted its focus to immuno-oncology with the acquisition of Trianta Immunotherapies, which was renamed...
advancing to the active stage. Exemplary are the GEM-CESAR, ASCENT and Immuno-PRISM clinical trials. After drug therapy has reduced a patient's cancer...
tomography imaging, for example, with zirconium-89 labeled antibodies (immuno-PET). For a decay table, see Maria Vosjan. "Zirconium-89 (89Zr)". Cyclotron...
barbital have also been used as pH buffers for biological research, e.g., in immuno-electrophoresis or in fixative solutions. Barbiturates are classified based...
Global Information